⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 25, 2024

Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials

Esther J. Beck Alexander D. Sherry Marcus A. Florez Ramez Kouzy Joseph Abi Jaoude Timothy A. Lin Avital M. Miller Adina H. Passy Gabrielle S. Kupferman Roshal R. Patel Fumiko Chino Victoria Serpas Higbie Christine M. Parseghian Michael J. Overman Bruce D. Minsky Charles R. Thomas Chad Tang Pavlos Msaouel Ethan B. Ludmir

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Distribution of the percentage of PROs published per trial.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Beck et al. (2024) studied this question.

synapsesocial.com/papers/68e5778bb6db64358751716c https://doi.org/10.1158/2767-9764.27101888.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
2Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
3Supplemental Table S2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
4Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
5Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024

Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
Supplemental Table S3 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024
Table 2 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials2024